{"id":3203,"date":"2013-11-06T10:00:00","date_gmt":"2013-11-06T10:00:00","guid":{"rendered":"https:\/\/www.xvivogroup.com\/us\/mfn_news\/xvivo-utokar-novel-studien-i-usa\/"},"modified":"2013-11-06T10:00:00","modified_gmt":"2013-11-06T10:00:00","slug":"xvivo-utokar-novel-studien-i-usa","status":"publish","type":"mfn_news","link":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-utokar-novel-studien-i-usa\/","title":{"rendered":"XVIVO ut\u00f6kar NOVEL studien i USA"},"content":{"rendered":"
University of Washington, Seattle, som \u00e4r en av de st\u00f6rre amerikanska lungtransplantations-klinikerna, har anslutits till den amerikanska NOVEL studien. Kliniken \u00e4r den tredje som har k\u00f6pt en XPS f\u00f6r detta \u00e4ndam\u00e5l. Intresset f\u00f6r STEEN Solution\u2122 metoden och XPS\u2122 \u00e4r fortsatt stort i USA.<\/strong><\/div>\n

XVIVO Perfusion AB (publ) fick i det f\u00f6reg\u00e5ende kvartalet klartecken fr\u00e5n FDA att \u00f6ka antalet center i den p\u00e5g\u00e5ende NOVEL studien i USA. Att University of Washington i Seattle kommer att delta i NOVEL studien leder till att fler lungsjuka patienter nu kan transplanteras.<\/span><\/p>\n

NOVEL studien designades f\u00f6r att p\u00e5 ett s\u00e4kert s\u00e4tt \u00f6ka antalet anv\u00e4ndbara lungor fr\u00e5n donatorpoolen och p\u00e5g\u00e5r nu p\u00e5 8 centra i USA. I studien j\u00e4mf\u00f6rs de kliniska resultaten efter transplantation av lungor som varmperfunderats efter att initialt ha bed\u00f6mts som oanv\u00e4ndbara med en kontrollgrupp av s\u00e5dana som initialt ha bed\u00f6mts som anv\u00e4ndbara. Hittills har 54 patienter i NOVEL studien genomg\u00e5tt transplantation efter varmperfusion med STEEN Solution\u2122 metoden. Resultaten s\u00e5 h\u00e4r l\u00e5ngt in i studien indikerar p\u00e5 att lungor som utv\u00e4rderats med STEEN Solution\u2122 i en XPS\u2122 inte skiljer sig s\u00e4kerhetm\u00e4ssigt och funktionellt fr\u00e5n lungor som transplanterats direkt. Dessa resultat indikerar allts\u00e5 p\u00e5 att fler donerade lungor p\u00e5 ett s\u00e4kert s\u00e4tt kommer att kunna anv\u00e4ndas till transplantation till gagn f\u00f6r patienterna p\u00e5 v\u00e4ntelista f\u00f6r nya lungor. Dessa resultat samst\u00e4mmer med de som publicerats fr\u00e5n centra i Kanada och Europa som kliniskt anv\u00e4nt STEEN Solution\u2122 med likv\u00e4rdig teknik.<\/span><\/p>\n

"Vi ser att intresset \u00f6kar i och utanf\u00f6r USA f\u00f6r bolagets teknologi f\u00f6r varmperfusion med STEEN Solution\u2122 och XPS\u2122 i och med att den kliniska erfarenheten blir mer spridd. Det \u00e4r sp\u00e4nnande att ledande klinikers intresse \u00e4r s\u00e5 stort att de investerar betydande belopp i utrustning f\u00f6r att kunna ansluta till NOVEL studien. Detta d\u00e4rf\u00f6r att det m\u00f6jligg\u00f6r f\u00f6r dem att kunna transplantera fler sv\u00e5rt lungsjuka patienter." s\u00e4ger Dr Magnus Nilsson, VD p\u00e5 XVIVO Perfusion. <\/span><\/p>\n

G\u00f6teborg 6 november 2013<\/span><\/p>\n

XVIVO Perfusion AB (publ)<\/span><\/p>\n

\n

F\u00f6r ytterligare information, v\u00e4nligen kontakta: <\/span><\/p>\n

Christoffer Rosenblad, CFO, tel: 031-788 21 59, e-post: christoffer.rosenblad@xvivoperfusion.com<\/a>
F\u00f6r ytterligare information om Xvivo Perfusions verksamhet h\u00e4nvisas till bolagets hemsida, www.xvivoperfusion.com<\/a><\/span><\/p>\n

Xvivo Perfusion\u00a0\u00e4r skyldigt att offentligg\u00f6ra informationen i detta pressmeddelande enligt lagen om v\u00e4rdepappersmarknaden och\/eller lagen om handel med finansiella instrument. Informationen l\u00e4mnades f\u00f6r publicering den\u00a06 november 2013 kl. 11:00.<\/span><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

University of Washington, Seattle, som \u00e4r en av de st\u00f6rre amerikanska lungtransplantations-klinikerna, har anslutits till den amerikanska NOVEL studien. Kliniken…<\/p>\n","protected":false},"template":"","class_list":["post-3203","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-lang-sv","mfn-news-tag-mfn-regulatory","mfn-news-tag-mfn-regulatory-vpml","mfn-news-tag-mfn-ci","mfn-news-tag-mfn-ci-other"],"acf":[],"yoast_head":"\nXVIVO ut\u00f6kar NOVEL studien i USA - XVIVO<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-utokar-novel-studien-i-usa\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"XVIVO ut\u00f6kar NOVEL studien i USA - XVIVO\" \/>\n<meta property=\"og:description\" content=\"University of Washington, Seattle, som \u00e4r en av de st\u00f6rre amerikanska lungtransplantations-klinikerna, har anslutits till den amerikanska NOVEL studien. Kliniken...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-utokar-novel-studien-i-usa\/\" \/>\n<meta property=\"og:site_name\" content=\"United States\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-utokar-novel-studien-i-usa\\\/\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-utokar-novel-studien-i-usa\\\/\",\"name\":\"XVIVO ut\u00f6kar NOVEL studien i USA - XVIVO\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\"},\"datePublished\":\"2013-11-06T10:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-utokar-novel-studien-i-usa\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-utokar-novel-studien-i-usa\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-utokar-novel-studien-i-usa\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"XVIVO ut\u00f6kar NOVEL studien i USA\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\",\"name\":\"United States\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"XVIVO ut\u00f6kar NOVEL studien i USA - XVIVO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-utokar-novel-studien-i-usa\/","og_locale":"en_US","og_type":"article","og_title":"XVIVO ut\u00f6kar NOVEL studien i USA - XVIVO","og_description":"University of Washington, Seattle, som \u00e4r en av de st\u00f6rre amerikanska lungtransplantations-klinikerna, har anslutits till den amerikanska NOVEL studien. Kliniken...","og_url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-utokar-novel-studien-i-usa\/","og_site_name":"United States","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-utokar-novel-studien-i-usa\/","url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-utokar-novel-studien-i-usa\/","name":"XVIVO ut\u00f6kar NOVEL studien i USA - XVIVO","isPartOf":{"@id":"https:\/\/www.xvivogroup.com\/us\/#website"},"datePublished":"2013-11-06T10:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-utokar-novel-studien-i-usa\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-utokar-novel-studien-i-usa\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-utokar-novel-studien-i-usa\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.xvivogroup.com\/us\/"},{"@type":"ListItem","position":2,"name":"XVIVO ut\u00f6kar NOVEL studien i USA"}]},{"@type":"WebSite","@id":"https:\/\/www.xvivogroup.com\/us\/#website","url":"https:\/\/www.xvivogroup.com\/us\/","name":"United States","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.xvivogroup.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news\/3203","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/media?parent=3203"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}